U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group
Trevi hits 4-year high as chronic cough therapy succeeds in study
U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin
U.S. STOCKS ON THE MOVE-Airbnb, Beacon, Redfin
Trevi jumps as chronic cough therapy succeeds mid-stage trial
Brief: Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC
Brief: Trevi Therapeutics Completes Enrollment For Phase 2B Coral Trial
Brief: Trevi Therapeutics Announces Positive Outcome From Sample Size Re-Estimation
Brief: Trevi Therapeutics Announces Positive Topline Results From Study Of Oral Nalbuphine
Trevi Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Trevi Therapeutics Provides Update On Haduvio's Clinical Development Program
Brief: Trevi Therapeutics Announces Oral Presentation On Data From Ph2a Canal Trial
Trevi Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Trevi Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Trevi Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Trevi Therapeutics Provides Business Updates
Brief: Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)